Standout Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cance... 2015 2026 2018 2022 2.9k
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
    Peter Schmid, Sylvia Adams et al. New England Journal of Medicine
  2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (2019)
    Peter Schmid, Hope S. Rugo et al. The Lancet Oncology
  3. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies (2015)
    Leisha A. Emens, Gary Middleton Cancer Immunology Research
  4. Breast Cancer Immunotherapy: Facts and Hopes (2017)
    Leisha A. Emens Clinical Cancer Research
  5. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017)
    Luc Dirix, István Takács et al. Breast Cancer Research and Treatment
  6. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer (2018)
    Leisha A. Emens, Cristina Cruz et al. JAMA Oncology
  7. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape (2017)
    Leisha A. Emens, Paolo A. Ascierto et al. European Journal of Cancer
  8. Targeting adenosine for cancer immunotherapy (2018)
    Robert D. Leone, Leisha A. Emens Journal for ImmunoTherapy of Cancer
  9. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis (2021)
    Leisha A. Emens, Sylvia Adams et al. Annals of Oncology
  10. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial (2020)
    Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology
  11. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study (2021)
    Leisha A. Emens, Luciana Molinero et al. JNCI Journal of the National Cancer Institute
  12. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy (2023)
    Suzanne L. Topalian, Patrick M. Forde et al. Cancer Cell
  13. Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision (2024)
    Leisha A. Emens, Pedro Romero et al. Journal for ImmunoTherapy of Cancer

Immediate Impact

21 by Nobel laureates 11 from Science/Nature 97 standout
Sub-graph 1 of 18

Citing Papers

Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
Analysis of Breast Cancer Mortality in the US—1975 to 2019
2024 Standout

Works of Leisha A. Emens being referenced

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
2021 Standout
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout

Author Peers

Author Last Decade Papers Cites
Leisha A. Emens 10452 5914 2517 3058 166 14.1k
Aurélien Marabelle 9849 5586 1520 3014 272 14.5k
Christian U. Blank 10302 6432 1132 1924 267 14.3k
Patrick A. Ott 10963 5386 1070 3420 236 15.1k
Mario Sznol 13619 7664 1533 4237 266 19.4k
Steven O’Day 9336 4551 1339 2353 195 12.6k
Jason J. Luke 7975 4708 1460 2083 290 12.6k
Axel Hoos 9043 4629 1087 2799 141 13.1k
Peter Schmid 8002 2496 3134 3424 203 10.6k
Bart Neyns 9568 4325 1527 2557 310 13.5k
Douglas B. Johnson 9445 3922 1090 2271 289 13.5k

All Works

Loading papers...

Rankless by CCL
2026